长春瑞滨加顺铂联合同步胸部放射治疗用于局部晚期非小细胞肺癌的临床研究  

Concurrent thoracic radiotherapy combining with vinorelbine and cisplatin in locally advanced nonsmall cell lung cancer

作　　者：周崧雯[1] 鲁冰[1] 徐建芳[1] 吕梅君[1] 徐瑛[1] 周彩存[1] 

机构地区：[1]同济大学附属上海市肺科医院肿瘤科,200433

出　　处：《国际肿瘤学杂志》2007年第2期147-149,共3页Journal of International Oncology

摘　　要：目的 探讨低剂量长春瑞滨（NVB）加顺铂（DDP）联合同步胸部放疗对局部晚期非小细胞肺癌（NSCLC）的疗效与安全性。方法 34例ⅢB期NSCLC患者接受NVB＋DDP联合同步放疗，放疗剂量在加～66Gy之间。结果客观缓解率为56％（19／34）；中位生存期16．5个月，1年生存率62％（21／34），2年生存率35％（12／34）。47％（16／34）患者发生不同程度的放射性食管炎，其中Ⅲ、Ⅳ度食管炎29％（10／34）；Ⅲ、Ⅳ度白细胞减少18％（6／34）；Ⅲ、Ⅳ度血小板减少3％（1／34）。结论 低剂量NVB＋DDP方案化疗联合同步胸部放射治疗对局部晚期NSCLC有效，患者可以耐受。Objective To investigate efficacy and toxicity of concurrent radiotherapy combining with low-dose vinorelbine plus cisplatin in locally advanced non-small cell lung cancer. Methods Thirty four patients with staged Ⅲ B non-small cell lung cancer were given concurrent thoracic radiotherapy combining with vinorelbine plus cisplatin. Total dose of radiation was from 40 to 66 Gy. Results Objective response rate of 56% （19/34） was achieved with median survival of 16.5 months, 1 year survival rate of 62% （21/34） and 2 year survival rate of 35% （ 12/34 ）. About 47% （16/34） of the patients developed varied degrees of esophagitis. WHO grade 3-4 esophagitis was seen in 29% （10/34） of the cases, grade 3-4 hypoleukemia and thrombocytopenia were seen in 18% （6/34）and 3% （1/34）respectively. Conclusion Concurrent radiotherapy combining with low-dose vinorelbine and cisplatin was effective and tolerable in the management of locally advanced nonsmall cell lung cancer.

关 键 词：癌 非小细胞肺 放射疗法 药物疗法 

分 类 号：R734[医药卫生—肿瘤]